A newly discovered COVID-19 variant, KP.3, is rising to become the dominant strain of the virus across the United States, according to the Centers for Disease Control and Prevention (CDC).
The Epoch Times contacted the CDC for comment on June 12.
“CDC predicts that KP.3 is growing and will become the most common SARS-CoV-2 lineage nationally,” a CDC spokesperson told several news outlets this week about the variant’s dominance. “CDC is working to better understand its potential impact on public health.”
But the data suggest that despite the increase in the KP.3 variant’s prevalence, the U.S. is currently seeing low levels of COVID-19 activity overall.
“Most key COVID-19 indicators are showing low levels of activity nationally, therefore the total number of infections this lineage may be causing is likely low,” the CDC spokesperson said.
Andy Pekosz, a molecular microbiology professor at Johns Hopkins University, said that the KP.2 and KP.3 variants do not appear to be more or less severe than prior COVID-19 strains. Instead, most people have COVID-19 antibodies either through a previous infection or vaccines.
COVID-19 Reports No Longer Required
Last month, the CDC said that hospitals will no longer have to report COVID-19-related hospital admissions, hospital capacity, or related information. The changes went into effect on May 1.The old “data will be archived as of May 10, 2024, and available at United States COVID-19 Hospitalization Metrics by Jurisdiction, Timeseries,” according to a statement posted on the CDC website at the time.
But the agency still encouraged medical facilities to report COVID-19 hospitalizations and related information to the federal health agency.
“A key lesson we learned from the COVID-19 pandemic is the importance of having reporting systems in place before an active emergency,” a CDC spokesperson said.
“These data have a significant and ongoing value for protecting patient health and safety as well as public health,” the statement added.
A U.S. Food and Drug Administration (FDA) panel, which authorized every previous COVID-19 vaccine that has been on the market, voted this past week to manufacture new booster shots to target strains derived from the JN.1 variant, which include KP.2 and KP.3.